参考文献/References:
[1].Bisbal F,Baranchuk A,Braunwald E,et al. Atrial failure as a clinical entity:JACC review topic of the week[J]. J Am Coll Cardiol,2020,75(2):222-232.
[2].Conen D,Wong JA,Sandhu RK,et al. Risk of malignant cancer among women with new-onset atrial fibrillation[J]. JAMA Cardiol,2016,1(4):389-396.
[3].Yun JP,Choi EK,Han KD,et al. Risk of atrial fibrillation according to cancer type:a nationwide population-based study[J]. JACC CardioOncol,2021,3(2):221-232.
[4].Dobrev D,Heijman J,Hiram R,et al. Inflammatory signalling in atrial cardiomyocytes:a novel unifying principle in atrial fibrillation pathophysiology[J]. Nat Rev Cardiol,2023,20(3):145-167.
[5].Mao XC,Yang CC,Yang YF,et al. Peripheral cytokine levels as novel predictors of survival in cancer patients treated with immune checkpoint inhibitors:a systematic review and meta-analysis [J]. Front Immunol,2022,13:884592.
[6].Kuo CL,Ponneri Babuharisankar A,Lin YC,et al. Mitochondrial oxidative stress in the tumor microenvironment and cancer immunoescape:foe or friend?[J]. J Biomed Sci ,2022,29(1):74.
[7].Meulendijks ER,Al-Shama RFM,Kawasaki M,et al. Atrial epicardial adipose tissue abundantly secretes myeloperoxidase and activates atrial fibroblasts in patients with atrial fibrillation[J]. J Transl Med,2023,21(1):366.
[8].Koene RJ,Prizment AE,Blaes A,et al. Shared risk factors in cardiovascular disease and cancer[J]. Circulation,2016,133(11):1104-1114.
[9].Mili N,Paschou SA,Goulis DG,et al. Obesity,metabolic syndrome,and cancer:pathophysiological and therapeutic associations[J]. Endocrine,2021,74(3):478-497.
[10].Yan T,Zhu S,Shi Y,et al. Pan-cancer analysis of atrial-fibrillation-related innate immunity gene ANXA4[J]. Front Cardiovasc Med,2021,8:713983.
[11].Zhang Z,Wang W,Zhang Y,et al. A potential link between aberrant expression of ECRG4 and atrial fibrillation[J]. Front Oncol,2023,13:1031128.
[12].Chakraborty P,Farhat K,Po SS,et al. Autonomic nervous system and cardiac?metabolism:links between autonomic and metabolic remodeling in atrial?fibrillation[J]. JACC Clin Electrophysiol,2023,9(7 Pt 2):1196-1206.
[13].Semeraro GC,Meroni CA,Cipolla CM,et al. Atrial fibrillation after lung cancer surgery:prediction,prevention and anticoagulation management[J]. Cancers,2021,13(16):4012.
[14].Saleh Y,Abdelkarim O,Herzallah K,et al. Anthracycline induced cardiotoxicity:mechanisms of action,incidence,risk factors,prevention,and treatment[J]. Heart Fail Rev,2021,26(5):115973.
[15].Tan R,Cong T,Xu G,et al. Anthracycline-induced atrial structural and electrical remodeling characterizes early cardiotoxicity and contributes to atrial conductive instability and dysfunction[J]. Antioxid Redox Signal,2022,37(1-3):19-39.
[16].Abdallah IB,Nasr SB,Chourabi C,et al. Gemcitabine-related atrial fibrillation:a case report and review of the literature[J]. Curr Drug Saf,2022,17(1):70-74.
[17].Alexandre J,Moslehi JJ,Bersell KR,et al. Anticancer drug-induced cardiac rhythm disorders:current knowledge and basic underlying mechanisms[J]. Pharmacol Ther,189:89-103.
[18].Kim CW,Choi KC. Effects of anticancer drugs on the cardiac mitochondrial toxicity and their underlying mechanisms for novel cardiac protective strategies[J]. Life Sci,2021,277:119607.
[19].Palaskas N,Lopez-Mattei J,Durand JB,et al. Immune checkpoint inhibitor myocarditis:pathophysiological characteristics,diagnosis,and treatment[J]. J Am Heart Assoc,2020,9(2):e013757.
[20].Yuan M,Tse G,Zhang Z,et al. The incidence of atrial fibrillation with trastuzumab treatment:a systematic review and meta-analysis[J]. Cardiovasc Ther ,2018,36(6):e12475.
[21].Baik AH,Oluwole OO,Johnson DB,et al. Mechanisms of cardiovascular toxicities associated with immunotherapies[J]. Circ Res,2021,128(11):1780-1801.
[22].Apte N,Dherange P,Mustafa U,Ya’qoub L,et al. Cancer radiation therapy may be associated with atrial fibrillation[J]. Front Cardiovasc Med,2021,8:610915.
[23].Buza V,Rajagopalan B,Curtis AB. Cancer treatment-induced arrhythmias:focus on chemotherapy and targeted therapies[J]. Circ Arrhythm Electrophysiol,2017,10(8):e005443.
[24].Kim KH,Oh J,Yang G,et al. Association of sinoatrial node radiation dose with atrial fibrillation and mortality in patients with lung cancer[J]. JAMA Oncol,2022,8(11):1624-1634.
[25].Pellegrini L,Novak U,Andres M,et al. Risk of bleeding complications and atrial fibrillation associated with ibrutinib treatment:a systematic review and meta-analysis [J]. Crit Rev Oncol Hematol,2021,159:103238.
[26].Yan S,Xu W,Fang N,et al. Ibrutinib-induced pulmonary angiotensin-converting enzyme activation promotes atrial fibrillation in rats[J]. iScience,2024,27(2):108926.
[27].Xiao L,Salem JE,Clauss S,et al. Ibrutinib-mediated atrial fibrillation attributable to inhibition of C-terminal Src kinase[J]. Circulation,2020,142(25):2443-2455.
[28].Writing Group Members,January CT,Wann LS,et al. 2019 AHA/ACC/HRS focused update of the 2014 AHA/ACC/HRS guideline for the management of patients with atrial fibrillation:a report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society[J]. Heart Rhythm,2019,16(8):e66-e93.
[29].Madnick DL,Fradley MG. Atrial fibrillation and cancer patients:mechanisms and management[J]. Curr Cardiol Rep,2022,24(10):1517-1527.
[30].Boriani G,Lee G,Parrini I,et al. Anticoagulation in patients with atrial fibrillation and active cancer:an international survey on patient management[J]. Eur J Prev Cardiol,2021,28(6):611-621.
[31].Lyon AR,López-Fernández T,Couch LS,et al. 2022 ESC Guidelines on cardio-oncology developed in collaboration with the European Hematology Association (EHA),the European Society for Therapeutic Radiology and Oncology (ESTRO) and the International Cardio-Oncology Society (IC-OS) [J]. Eur Heart J,2022,43(41):4229-4361.
[32].Tafur AJ,McBane R 2nd,Wysokinski WE,et al. Predictors of major bleeding in peri-procedural anticoagulation management[J]. J Thromb Haemost,2012,10(2):261-267.
[33].Fanola CL,Ruff CT,Murphy SA,et al. Efficacy and safety of edoxaban in patients with active malignancy and atrial fibrillation:analysis of the ENGAGE AF-TIMI 48 trial[J]. J Am Heart Assoc,2018,7(16):e008987.
[34].Peixoto de Miranda ?JF,Takahashi T,Iwamoto F,et al. Drug-drug interactions of 257 antineoplastic and supportive care agents with 7 anticoagulants:a comprehensive review of interactions and mechanisms[J]. Clin Appl Thromb Hemost,2020,26:1076029620936325.
[35].Watson N,Al-Samkari H. Thrombotic and bleeding risk of angiogenesis inhibitors in patients with and without malignancy [J]. J Thromb Haemost,2021,19(8):1852-1863.
[36].Lazar S,Goldfinger LE. Platelets and extracellular vesicles and their cross talk with cancer[J]. Blood,2021,137(23):3192-3200.
[37].Ganatra S,Sharma A,Shah S,et al. Ibrutinib-associated atrial fibrillation[J]. JACC Clin Electrophysiol,2018,4(12):1491-1500.
[38].Bickford CL,Agarwal R,Urbauer DL,et al. Efficacy and safety of ibutilide for chemical cardioversion of atrial fibrillation and atrial flutter in cancer patients[J]. Am J Med Sci,2014,347(4):277-281.
[39].Ganatra S,Abraham S,Kumar A,et al. Efficacy and safety of catheter ablation for atrial fibrillation in patients with history of cancer[J]. Cardiooncology,2023,9(1):19.
相似文献/References:
[1]贺鹏康,周菁.心房颤动治疗新技术——冷冻球囊消融[J].心血管病学进展,2016,(1):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
HE Pengkang,ZHOU Jing.Cryoballoon Ablation, A Novel Technology for Atrial Fibrillation Treatment[J].Advances in Cardiovascular Diseases,2016,(9):1.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.001]
[2]都明辉,施海峰*,佟佳宾,等.心房颤动消融相关性无症状性脑缺血[J].心血管病学进展,2016,(1):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
DU Minghui,SHI Haifeng*,TONG Jiabin,et al.Silent Cerebral Ischemia Related to Atrial Fibrillation Ablation[J].Advances in Cardiovascular Diseases,2016,(9):3.[doi:10.16806/j.cnki.issn.1004-3934.2016.01.002]
[3]郑环杰,综述,肖骅,等.心房颤动抗栓治疗研究进展[J].心血管病学进展,2016,(2):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
ZHENG Huanjie,XIAO Hua.Progress of Antithrombotic Therapy in Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):142.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.012]
[4]张清,综述,罗素新,等.新型Xa 因子抑制剂———依度沙班在心房颤动患者抗凝治疗中的研究进展[J].心血管病学进展,2016,(2):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
ZHANG Qing,LUO Suxin,TANG Jiong.Novel Factor Xa Inhibitors—Edoxaban in Prevention of Stroke in
Patients with Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):151.[doi:10.16806/j.cnki.issn.1004-3934.2016.02.014]
[5]胡红玲,综述,罗素新,等.预防非瓣膜性心房颤动性脑卒中的治疗新进展[J].心血管病学进展,2016,(3):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
HU Hongling,LUO Suxin.New Progress in the Treatment for Cerebral Apoplexy of Nonvalvular
Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):250.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.009]
[6]王超,杨国澍,综述,等.关附甲素治疗心房颤动的研究进展[J].心血管病学进展,2016,(3):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
WANG Chao,YANG Guoshu,CAI Lin,et al.Research Progress of the Treatment of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):254.[doi:10.16806/j.cnki.issn.1004-3934.2016.03.010]
[7]徐小东,综述,杨东辉,等.决奈达隆治疗心房颤动的现状及展望[J].心血管病学进展,2016,(4):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
XU Xiaodong,YANG Donghui.Status and Prospect of Dronedarone in Treating Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2016,(9):368.[doi:10.16806/j.cnki.issn.1004-3934.2016.04.011]
[8]张莎,储国俊,吴弘.经导管左心耳封堵术的临床应用进展[J].心血管病学进展,2015,(5):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
ZHANG Sha,CHU Guojun,WU Hong.Clinial Application Advances in Left Atrial Appendage Closure[J].Advances in Cardiovascular Diseases,2015,(9):547.[doi:10.3969/j.issn.1004-3934.2015.05.006]
[9]汪俊,杨浩.心房颤动射频消融的术式演变[J].心血管病学进展,2015,(5):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
WANG Jun,YANG Hao.Evolution of Radiofrequency Ablation of Atrial Fibrillation[J].Advances in Cardiovascular Diseases,2015,(9):574.[doi:10.3969/j.issn.1004-3934.2015.05.013]
[10]赵璐,苏立.心房颤动与离子通道重构研究进展[J].心血管病学进展,2015,(5):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
ZHAO Lu,SU Li.Research Progress of Atrial Fibrillation and Ion Channel Remodeling[J].Advances in Cardiovascular Diseases,2015,(9):580.[doi:10.3969/j.issn.1004-3934.2015.05.014]
[11]薛祚臣 程爱娟.心房颤动合并肿瘤患者的治疗现状及进展[J].心血管病学进展,2021,(9):773.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]
XUE Zuochen,CHENG Aijuan.Status and Progress of Treatment in Patients with Atrial Fibrillation and Tumor[J].Advances in Cardiovascular Diseases,2021,(9):773.[doi:10.16806/j.cnki.issn.1004-3934.2021.09.000]